MedPath

Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus

Phase 2
Completed
Conditions
Keratoconus
Interventions
Procedure: Riboflavin/UVA crosslinking
Procedure: Sham treatment
Registration Number
NCT00626717
Lead Sponsor
University Hospital Freiburg
Brief Summary

Background: Corneal cross linking is a procedure that induces collagen cross linking of the corneal stroma due to release of reactive oxygen radicals upon activation of topically applied riboflavine A by UVA exposure. This procedure might be capable of reducing keratocouns progression.

Purpose: Although there are no randomised controlled trials on the effectiveness of corneal cross linking for the treatment of keratoconus it gains more and more importance in the general clinical setting. Therefore, the investigators started such randomised, placebo controlled, double blinded, multicenter trial to find out if this treatment is as effective as it promises to be.

Methods: Randomised, placebo controlled, double blinded, multicenter trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Only early Keratoconus (Contact lens fitting)
  • Progression of Ametropia.
  • Corneal thickness > 450µm
Exclusion Criteria
  • Further ophthalmic diseases
  • History of ocular surgery
  • Pregnancy, brest feeding
  • Allergy against Riboflavin
  • End stage Keratoconus

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Riboflavin/UVA crosslinking-
2Sham treatment-
Primary Outcome Measures
NameTimeMethod
Endothelial cell loss3 years
Keratoconus progression3 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Eye Hospital Freiburg

🇩🇪

Freiburg, Baden-Württemberg, Germany

© Copyright 2025. All Rights Reserved by MedPath